摘要
目的观察国产和进口氯吡格雷对冠心病患者经皮冠状动脉介入治疗（PCI）术后抗血小板的临床疗效和安全性。方法将408例冠心病患者随机分为两组，其中国产氯吡格雷治疗组210例，进口氯吡格雷治疗组198例，两组患者均于PCI术前3d开始服用氯吡格雷，首剂300mg，以后每日75mg，共服用12个月。观察两组患者PCI术后急性血栓、亚急性血栓、晚期血栓的发生率；术后主要心血管不良事件包括心源性死亡、再次心肌梗死、再发心绞痛、继发心力衰竭及再次入院治疗、术后再狭窄及临床出血事件包括脑出血、消化道出血及皮下出血的对比情况。结果两组患者的主要不良心脏事件及各种出血并发症比较差异无统计学意义。结论国产和进口两种氯吡格雷的临床疗效相同，安全可靠。
Objective To observe the curative effects and safety of home-made clopidogrel （Talcorn） and imported clopidogrel （Plavix） in patients underwent percutaneous transluminal coronary implantation（PCI）. Methods A total of 408 coronary heart disease（CHD） patients were randomly divided into two groups including Talcom group （ n = 210）and Plavix group （ n = 198 ）. Clopidogrel were given to all CHD patients 3 days before PCI. The first dosage of 300 mg was taken, then 75 mg/d for one year. The events of acute-subacute and late thrombosis in stent were observed. The bleeding events and vascular restenosis were also observed. Results There were no significant differences of the incidences of acute, subacute, late thrombosis and bleeding events in stent of two groups during 12 months after PCI. Conclusions Home-made clopidogrel and imported clopidogrel are both effective and safe for the treatment of patients underwent PCI.
出处
《中国实用医刊》
2013年第8期8-9,共2页
Chinese Journal of Practical Medicine
